Cargando…
PGC−1α Promoter Methylation in Parkinson’s Disease
The etiopathogenesis of sporadic Parkinson’s disease (PD) remains elusive although mitochondrial dysfunction has long been implicated. Recent evidence revealed reduced expression of peroxisome proliferator-activated receptor gamma coactivator−1 α (PGC−1α) and downstream regulated nuclear encoded res...
Autores principales: | Su, Xiaomin, Chu, Yaping, Kordower, Jeffrey H., Li, Bin, Cao, Hong, Huang, Liang, Nishida, Maki, Song, Lei, Wang, Difei, Federoff, Howard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552803/ https://www.ncbi.nlm.nih.gov/pubmed/26317511 http://dx.doi.org/10.1371/journal.pone.0134087 |
Ejemplares similares
-
Immune Responses in Parkinson's Disease: Interplay between Central and Peripheral Immune Systems
por: Su, Xiaomin, et al.
Publicado: (2014) -
PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
por: Corona, Juan Carlos, et al.
Publicado: (2014) -
Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease
por: Hiller, Benjamin M., et al.
Publicado: (2022) -
Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases
por: Huang, Liang, et al.
Publicado: (2013) -
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson’s disease
por: Chu, Yaping, et al.
Publicado: (2020)